

ASX Announcement

14 November 2024

Australian patent accepted for BREASTEST® technology

- **Grant of this patent will provide additional IP protection in Australia for methods and lipids that form BCAL's BREASTEST®**
- **With the imminent commercial launch of BREASTEST® in Australia, BCAL requested accelerated examination of this BCAL-developed patent to strengthen IP protection**
- **BCAL's growing patent portfolio includes in-licensed and BCAL-developed IP**

Breast cancer screening and diagnostic company BCAL Diagnostics Limited (ASX:BDX, 'BCAL' or the 'Company') is pleased to announce that Australian Patent No 2023258393 entitled "*Diagnostic signature*" was accepted by IP Australia and is expected to be granted to BCAL Diagnostics Ltd. The patent covers methods and lipids that together form important elements of the Company's BREASTEST® technology.

This is the first BCAL-developed patent to be accepted, which arises from the Company's first patent family. BCAL requested accelerated examination of patent no 2023258393 in Australia to strengthen the IP protection of BCAL's proprietary blood test technology, prior to BREASTEST® commercial launch. Australian patent no 2023258393 is due to expire on 10 May 2043, providing IP protection for the technology through to this date.

The Company has also filed national phase applications for this first patent family in jurisdictions that align with expected major markets for BREASTEST®, which includes the United States, Canada, Japan, China and Europe. BCAL anticipates that the successful examination of the claims in this patent family in Australia provides confidence of similarly successful examinations in the selected jurisdictions with regards to novelty and inventiveness.

BCAL now has two BCAL-developed patent families that have been filed internationally via the Patent Cooperation Treaty (PCT). BCAL submitted the PCT filing for the second BCAL-developed patent family on 31 October 2024. This is expected to be published in the next 6 months.

These filings build on BCAL's existing portfolio of in-licensed patents that includes 23 granted patents and 4 pending patents across jurisdictions including the United States, Australia, Canada, Japan and multiple jurisdictions within Europe.

Chief Executive Officer, Shane Ryan commented: "*The acceptance of this patent is a crucial step in BCAL's journey to bring BREASTEST® to the global market, representing a large amount of research and development that BCAL has undertaken over many years. Building layers of IP protection around our technology is a key priority for us as it underpins our core commercialisation strategy and competitive advantage as we progress towards providing an innovative, novel diagnostic tool for breast cancer.*"

This announcement has been approved for release by the Board of BCAL Diagnostics Limited.

ENDS

For further information:

Jayne Shaw

Executive Chair
Jshaw@bcaldiagnostics.com

Shane Ryan

Chief Executive Officer
sryan@bcaldiagnostics

About BCAL Diagnostics

BCAL Diagnostics Limited is an Australian screening and diagnostic company committed to the early, accurate diagnosis of breast cancer, and therefore early intervention and improved outcomes for women. Over the past decade BCAL has developed a non-invasive blood test for the detection of breast cancer, with results to date demonstrating excellent performance independent of breast tissue density. The test is initially designed to complement current imaging technologies, such as the mammogram, with the aim of becoming a monitoring and screening tool suitable for women of all ages and backgrounds in any location. With more than two million new cases of breast cancer diagnosed globally each year, a substantial opportunity exists for BCAL to improve patient outcomes.

Founded in 2010, BCAL is headquartered in Sydney and listed on the Australian Securities Exchange (ASX: BDX). For more information: <https://www.bcaldiagnostics.com/>